28-30 January 2019
Paris, France
View Event Guide

Day One
Tuesday 29 January 2019

Day Two
Wednesday 30 January 2019

08.00
Morning Coffee & Registration

08.50
Chairperson Opening Remarks

Moving to Mechanism – A New Focus on Establishing Disease Causation

09.00
Definition of a Healthy Microbiome and if Disturbed – How to Shape It Back to Normal

  • Pr Lars Engstrand Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet

09.30
Identification of Microbiome-Based Biomarkers and Challenges Associated with Their Application: Case Studies from Obesity, IBD, and Cancer

  • Julia Cope Director of Scientific Operations, Diversigen

10.00
Investigating the Causal Role of the Microbiota in Immune- Mediated Diseases

10.30
Microbiome Characterisation: Standards, Sequencing, and Bioinformatics

11.00
Speed Networking

11.30
Morning Refreshments

12.00 Culture-Based Microbiome Analysis in Personalised Medicine and Birth Cohort Studies

Trevor Lawley, Chief Scientific Officer, Microbiotica

12.20 Rational in Silico Design and Validation of a Novel LBP for Ulcerative Colitis

Daniel van der Lelie, Chief Scientific Officer, Gusto Global

12.40 Standardising Microbiomics – Removing Bias in Collection, Purification and Analyses

Thomas Kuri, Scientific Director, Zymo Research

12.50 Identifying Gut Bacterial Metabolites with Immuno-Modulator Activity for the Treatment of Chronic Respiratory Diseases

Jim Brown, Director of Computational Biology & Senior
Fellow, GSK

12.00 Development of Oral Live Bio-Therapeutic Products – a CDMOs Perspective

Ryan Wilson, Head of Live-Bio Programmes, Quay Pharma

12.30 Scale up and GMP Manufacture of Live Biotherapeutic Products

Jason Ryan, Head of Upstream Manufacturing, Luina Bio

12.40 Faecal Microbiota Transplantation (FMT): regulation, commercialisation and future perspectives

James McIlroy, Founder & Chief Business Officer, EnteroBiotix

13.00 FMT-based discovery: from platform to product

Luc Sterkman, Chief Executive Officer, Caelus Health

13.20
Lunch & Networking

14.20 Prioritising Indications for Microbiome Therapeutics:Where do we go after C.difficile and UC?

Jessica Schneider, Associate Scientific Director, Takeda

14.40 Microbiome Alliances at Ferring Pharmaceuticals

Kristin Wannerberger, Director of Partnerships, Ferring Pharmaceuticals

15.00 The Value and Meaning of Partnerships in the Microbiome Space

Lee Jones, Chief Executive Officer, Rebiotix

15.20 Panel Discussion: New Perspectives on Pharma & Biotech Partnerships in the Microbiome

Jessica Schneider, Associate Scientific Director, Takeda
Kristin Wannerberger, Director of Partnerships, Ferring Pharmaceuticals
Lee Jones, Chief Executive Officer, Rebiotix
Mike Romanos, Chief Executive Officer, Microbiotica

14.20 Making the Difference in LBP Drug Development and Manufacturing

Adrien Nivoliez, Chief Executive Officer, Biose industrie

14.30 Investigating the Human Microbiome in GVHD/GVL

Pr Mohamed Mohty MD, Professor of Hematology and Head of Hematology Department, Saint-Antoine Hospital and University Pierre & Marie Curie

14.50 Developing a New Generation of First-In-Class High Diversity Microbiome Biotherapeutics to Treat Life-Threatening Diseases

Herve Affagard, Chief Executive Officer, MaaT Pharma

15.10 Panel Presentation: One Size Doesn’t Fit All - Using Advanced Microbiome Clinical Data to Tailor a Therapeutic to the Disease

Lilia Bouchinha, Bioinformatics Project Manager, MaaT Pharma
Ken Blount, Chief Scientific Officer, Rebiotix
David Cook, Chief Scientific Officer, Seres Therapeutics
Bruce Roberts, Chief Scientific Officer, Vedanta Biosciences

15.40
Afternoon Refreshments & Networking

16.30 Delivery, Survival, Engraftment & Activity of LBPs in the Gastrointestinal Tract

Massimo Marzorati, Chief Executive Officer, ProDigest

16.00 Rollercoaster Ride for the Pioneers in Microbiome Clinical Programme Development

Ken Blount, Chief Scientific Officer, Rebiotix

16.20 Studying Microbiome-Host Interactions to Translate Microbiome Drugs into the Clinic

David Cook, Chief Scientific Officer, Seres Therapeutics

16.40 Clinical Considerations of Rationally Designed Live Bacterial Cocktails

Bruce Roberts, Chief Scientific Officer, Vedanta Biosciences

Innovation Power Hour: Start-Up Showcase

17.10
Establishing the Role of Biofilms in Human Microbiome Discovery

17.30
Novel Therapeutic Approaches Targeting the Microbiome in Metabolic Diseases

17.50
Pioneering the Microbiome Oral Delivery for First-in-Man Studies

18.20
title

18.30
Close of Conference Day One and Evening Drinks Reception Hosted by the Microbiome Movement

19.20
Close of Conference Day One